GRFS: Rega marang dodolan Grifols SA
The calculated price-to-sales ratio demonstrates the position of Grifols, S.A. (GRFS) as a global leader in the B2B plasma-derived medicines segment with a high market share in rare pathologies. The value of 0.30 shows the latest metric value amid cost reductions and growth in raw material collection. High barriers to entry and resource scarcity allow the issuer to effectively manage the pricing power of life-saving medications.
Rincian analitis perusahaan Grifols Group (GRFS)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Koefisien Total Utang marang Modal Grifols, S.A.|GRFS - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang ekuitas Grifols Biemat|GRFS - Utang perusahaan|Utang-utang marang nilai buku Grifols Group|GRFS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Grifols|Koefisien jangkoan perantara grifols.com
- rincian bathi lan kelipatan pasar:
GRFS - Penghasilan resik|Penghasilan resik sing dikarepake Grifols, S.A.|GRFS - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Grifols SA|GRFS - Pangali rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Grifols Group|GRFS - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Grifols|GRFS - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan grifols.com|GRFS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Grifols, S.A.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:GRFS - grifols.com
Grifols, S.A. (GRFS) generates revenue through the sale of high-tech plasma derivatives and diagnostic equipment, making the P/S ratio a key indicator for valuing the business's market capitalization relative to its operational volumes. The current value of 0.30 reflects investors' willingness to pay per unit of sales, while current P/S dynamics allow for a comparison of this multiple against historical extremes to identify whether the asset is overbought or undervalued.
Pesaing Grifols, S.A.
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Multiplikator rega marang pendapatan Protagonist Corp (PTGX)|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|kiniksa.com - Rasio kapitalisasi pasar marang pendapatan|ADPT (Adaptive Biotechnologies Corporation) - Multiplikator P/S|Celldex Therapeutics Inc (CLDX) - Koefisien rega marang pendapatan|Multiplikator P/S AUPH|BCRX: Rasio rega marang dodolan|Rasio rega marang pendapatan Vera Therapeutics, Inc. VERA|dianthustx.com (DNTH) - Rega marang dodolan|PHVS - Rasio rega marang pendapatan|ABCL: Rasio rega marang pendapatan|Tourmaline Corp (TRML) - Rasio rega marang pendapatan|PGEN - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan PHAR|NKTR: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Upstream Bio (UPB)|Koefisien rega marang pendapatan Zenas Bio|Immunome Corp - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - Multiplikator P/S|SEPN - Multiplikator P/S|PVLA (Pieris Pharmaceuticals, Inc.) - Kapitalisasi marang pendapatan|SVRA - Koefisien rega marang pendapatan|RIGL (Rigel Pharmaceuticals Inc) - Multiplikator P/S|ANAB - Multiplikator rega marang pendapatan|Rasio rega marang pendapatan Astria Therapeutics (ATXS)|ENGN (engene.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S RAPT (RAPT Therapeutics)|JBIO (Aerovate Therapeutics, Inc.) - Rasio rega marang dodolan|ACRS - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Rasio rega marang pendapatan|Rasio rega marang dodolan CABA (cabalettabio.com)|VTYX (Ventyx Biosciences, Inc.) - Multiplikator P/S|THTX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AVTX|Multiplikator P/S Eledon Pharmaceuticals, Inc (ELDN)|Rasio rega marang pendapatan Agenus AGEN|Rasio kapitalisasi pasar marang pendapatan CLYM|ZURA - Rasio rega marang pendapatan|aTyr Pharma Inc (ATYR) - Kapitalisasi marang pendapatan|ADAG: Multiplikator P/S|Ikena Oncology (IMA) - Multiplikator P/S|Kapitalisasi marang pendapatan STTK|EQ: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CNTB|Koefisien rega marang pendapatan immunic-therapeutics.com|Rasio rega marang pendapatan Atara Bio ATRA|IFRX - Kapitalisasi marang pendapatan|XFOR - Rasio rega marang pendapatan|Adicet Bio (ACET) - Kapitalisasi marang pendapatan|CELU (celularity.com) - Kapitalisasi marang pendapatan|INmune Bio Inc (INMB) - Multiplikator P/S|Rasio rega marang pendapatan Barinthus Bio|Rasio kapitalisasi marang pendapatan KZR (Kezar Life Sciences Inc)|Multiplikator P/S SABS|AKTX - Rega marang dodolan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Multiplikator rega marang pendapatan Q32 Bio Inc|GOVX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan EDSA (Edesa Biotech Corp)|IBIO: Multiplikator P/S|CARM - Koefisien rega marang pendapatan|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Bolt Bio - Rasio rega marang dodolan|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|APVO - Rega marang dodolan|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|Aditxt Inc. - Rasio rega marang pendapatan|GRI - Rasio rega marang pendapatan|Koefisien rega marang pendapatan XORTX Therapeutics Inc XRTX|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|Revelation Biosciences Corp - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Indaptus Therapeutics|scinai.com (SCNI) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|Koefisien rega marang pendapatan affimed.com|Multiplikator P/S ALLK (Allakos)|Multiplikator P/S HOOKIPA Pharma, Inc. HOOK|IGMS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan iteostherapeutics.com ITOS|OCEA: Multiplikator P/S|Multiplikator rega marang pendapatan TC BioPharm (Holdings) Plc TCBP|Rasio rega marang pendapatan Third Harmonic Bio, Inc
